000100.KO Yuhan Corp.
- Market cap
- KRW 6.18T
- P/E
- 25.0x
- P/B
- 2.45x
- ROE
- 8.2%
- Dividend yield
- 0.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 000100.KO undervalued?
Graham number000100.KO trades 64.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yuhan Corp. fundamental analysis
No fundamental analysis for Yuhan Corp. yet.
Yuhan Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yuhan Corp.
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides API…
Full company profileYuhan Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yuhan Corp. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.32T | 1.46T | 1.52T | 1.48T | 1.62T | 1.69T | 1.78T | 1.86T | 2.07T | 2.19T | 2.33T |
| Gross Profit | 389B | 425B | 414B | 431B | 558B | 525B | 518B | 566B | 689B | 730B | 755B |
| Operating Income | 97.8B | 88.7B | 50.1B | 12.5B | 84.3B | 48.6B | 36.0B | 57.0B | 54.9B | 104B | 151B |
| EBITDA | - | 202B | 152B | 117B | 302B | 182B | 141B | 186B | 139B | 307B | 335B |
| Net Income | 161B | 109B | 57.5B | 40.0B | 193B | 103B | 95.1B | 136B | 70.7B | 194B | 195B |
| EPS | - | 1,771 | 937 | 654 | 3,151 | 1,522 | 1,351 | 1,938 | 958 | 2,636 | 2,645 |
| Balance Sheet | |||||||||||
| Total Assets | 2.05T | 2.09T | 2.17T | 2.12T | 2.39T | 2.46T | 2.47T | 2.81T | 2.94T | 3.22T | 3.33T |
| Total Liabilities | 549B | 488B | 522B | 467B | 547B | 528B | 465B | 712B | 791B | 859B | 859B |
| Shareholders' Equity | 1.50T | 1.60T | 1.64T | 1.65T | 1.84T | 1.93T | 1.99T | 2.05T | 2.10T | 2.31T | 2.39T |
| Cash & Short-term Investments | 245B | 257B | 241B | 274B | 353B | 254B | 293B | 299B | 306B | 349B | 428B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 74.1B | 126B | 93.5B | 66.0B | 28.8B | 99.0B | 99.5B | 128B | 54.6B | 106B | 162B |
| Capital Expenditure | 84.6B | 56.8B | 46.0B | 42.8B | 51.5B | 46.2B | 65.8B | 72.4B | 134B | 145B | 176B |
| Free Cash Flow | - | 66.2B | 44.9B | 19.3B | -62.3B | 17.1B | 5.15B | 55.3B | -79.3B | -38.5B | -13.8B |
| Ratios | |||||||||||
| ROE | 10.8% | 6.8% | 3.5% | 2.4% | 10.5% | 5.3% | 4.8% | 6.6% | 3.4% | 8.4% | 8.2% |
| ROA | 7.9% | 5.2% | 2.6% | 1.9% | 8.1% | 4.2% | 3.8% | 4.8% | 2.4% | 6.0% | 5.8% |
| Net Profit Margin | 12.2% | 7.5% | 3.8% | 2.7% | 11.9% | 6.1% | 5.4% | 7.3% | 3.4% | 8.9% | 8.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Yuhan Corp. dividends
- Dividend yield
- 0.61%
- Forward dividend
- 600.00 KRW
- Payout ratio
- 19.3%
- Ex-dividend date
- Feb 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 37.5B | 509 | 19.3% |
| 2024 | KRW 32.1B | 436 | 45.5% |
| 2023 | KRW 27.3B | 388 | 20.0% |
| 2022 | KRW 26.1B | 370 | 27.4% |
| 2021 | KRW 24.9B | 370 | 24.3% |
| 2020 | KRW 23.8B | 389 | 12.3% |
| 2019 | KRW 22.9B | 374 | 57.3% |
| 2018 | KRW 21.9B | 358 | 38.2% |
| 2017 | KRW 20.7B | 337 | 19.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.05:1 on Dec 27, 2023.
Who owns Yuhan Corp.
- Insiders 31.30%
- Institutions 24.76%
- Public & others 43.94%
- Shares outstanding 73.6M
- Free float 61.8M
Yuhan Corp. company profile
- Company name
- Yuhan Corp.
- Ticker
- 000100.KO
- ISIN
- KR7000100008
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,082
- Fiscal year end
- December
- Address
- 74, Noryangjin-ro, Seoul, South Korea
- Phone
- 82 2 828 0181
- Website
- yuhan.co.kr
About Yuhan Corp.
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Yuhan Corp. management
10- Mr. Wook-Je ChoPresident, CEO & Executive Director · born 1955
- Mr. Yeul-Hong KimPresident, R&D Director & Executive Director · born 1959
- Mr. Byung-Man LeeVP, Head of the Mngt. HQ. & Internal Accounting Manager · born 1958
- Ms. Eunhee ParkMD & Director of Legal Affairs · born 1971
- Mr. Joo-Yong ChungMD & Head of Marketing Department · born 1967
- Mr. Jae-Kyo KimVP & Head of the Pharmaceutical Business Division · born 1968
- Mr. Sung-Soo KimMD & Head of the Lifestyle Health Business Division · born 1964
- Mr. Jun-Hwan KimMD & Head of Biopharmaceutical Division · born 1975
- Mr. Min Chul ChoMD & ESG Management Director · born 1965
- Mr. Chanhwan ParkMD & Head of Management Department · born 1972